1. Author: Richard H. Simon, M.D., 2008-2010 License: Unless otherwise noted, this material is made available under the terms of the the Creative Commons Attribution – Share Alike 3.0 License: http://creativecommons.org/licenses/by-sa/3.0/ We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material. Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use. Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition. Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.

2. Citation Key for more information see: http://open.umich.edu/wiki/CitationPolicy Use + Share + Adapt Make Your Own Assessment Creative Commons – Attribution License Creative Commons – Attribution Share Alike License Creative Commons – Attribution Noncommercial License Creative Commons – Attribution Noncommercial Share Alike License GNU – Free Documentation License Creative Commons – Zero Waiver Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ Public Domain – Expired: Works that are no longer protected due to an expired copyright term. Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105) Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain. Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that your use of the content is Fair. To use this content you should do your own independent analysis to determine whether or not your use will be Fair. { Content the copyright holder, author, or law permits you to use, share and adapt. } { Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. } { Content Open.Michigan has used under a Fair Use determination. }

3. Cystic Fibrosis v Richard H. Simon Pulmonary and Critical Care Medicine Department of Internal Medicine Fall 2008

4. Objectives v Understand: D The genetic nature of cystic fibrosis (CF) D The pathophysiology of CF lung disease v Know how to diagnose CF v Learn the basic approach to treating CF lung disease

5. Cystic Fibrosis v Inherited disease D Autosomal recessive v Gene cloned in 1989: “CFTR” D Cystic Fibrosis Transmembrane conduction Regulator v 1601 mutations in CFTR known to cause CF v An extensive amount of information is known about CFTR Science, September 1989

6. Schematic Representation of CFTR Genetic Disorder Research Project Wiki Site

7. Pathophysiology of CF CFTR Dysfunction Disease manifestations D Lungs D Sinuses D Pancreas D Liver D Bones D Vas deferens ?

8. Airway Cross Sectional View Knowles & Boucher 2002;109:571 Epithelial cell layer Mucus layer Pericellular layer with cilia

9. Required Geometry for Effective Mucociliary Clearance Knowles & Boucher 2002;109:571

10. Pathophysiology of CF Lung Disease Source Undetermined

11. Consequences of CFTR Deficiency on Airway Clearance Knowles & Boucher 2002;109:571

12. Pathophysiology of CF Lung Disease CF Gene Mutation Ion Transport Abnormalities Altered Airway Environment Inflammation Infection TissueDamage R. Simon

13. Pathophysiology of CF Lung Disease Bronchiectasis Death Chronic Respiratory Failure CF Gene Mutation Recurrent Bronchitis Source Undetermined R. Simons

14. Prevalence of Infections in CF Patients 0 20 40 60 80 100 0 to 1 2 to 5 6 to 10 11 to 17 18 to 24 25 to 34 35 to 44 45+ Age (years) Percent Cystic Fibrosis Foundation Patient Registry Data. 2005 P. aeruginosa S. aureus MRSA H. influenza S. maltophilia B. cepacia

15. Natural History of CF Lung Infections v Ps. aeruginosa or B. cepacia complex species persist in the lung v True infection, not “colonization” v Difficulty in eradicating infection: D Intrinsic antibiotic resistance D Acquired antibiotic resistance D Poor antibiotic penetration into secretions D Alginate produced by mucoid Ps. (biofilms) D CF-related defects in mucosal (but not systemic) defenses

16. Diagnostic criteria for cystic fibrosis Part 1: Clinical Manifestation of Disease v At least one of the following: 1) One or more clinical manifestations of CF ; Meconium ileus ; Chronic bronchitis / bronchiectasis ; Chronic infection of the paranasal sinuses ; Pancreatic insufficiency ; Salt loss syndromes ; Male infertility due to congenital bilateral absence of the vas deferens 2) Positive newborn screening test 3) History of CF in a sibling

17. Diagnostic Criteria for Cystic Fibrosis Part 2: Laboratory evidence of CFTR abnormality v At least one of the following: 1)Elevated sweat chloride test 2)Identification of a mutation in each CFTR gene known to cause CF 3)In vivo demonstration of characteristic abnormalities in ion transport across nasal epithelium (not widely available)

18. Sweat Test for Diagnosis of CF 020406080100120140160180 mEq/L 0 300 600 900 1200 1500 1800 0 600 120 180 240 Number of normal controls Number of patients with CF Controls n=4269 CF n=920 Shwachman H, Mahmoodian A. Mod Prob Pediatr 1967;10:158

19. Use of Genotyping to Diagnose CF v 1601 CFTR mutations known to cause CF v Only 25 mutations have a frequency > 0.1% Frequency, % 010203040506070 R347P 3849+10kbC  T Δ I507 R117H R1162X 1717-1G  A R553X 621+1G  T W1282X N1303KG551DG542X ΔF508 CF Genetic Analysis Consortium Population Frequency of Specific CFTR Mutations Causing CF

20. Genotyping for CF Diagnosis v Current commercial screening tests D Look for presence of between 25 - 100 mutations D These will detect a CF allele only ~90% of time v For a group of patients with known CF, genotyping would be diagnostic in only ~81% of patients v  Screening for most common mutations is not as sensitive as sweat testing (98%) to diagnose classic CF

21. Genetic Diagnosis of CF v Tests becoming commercially available for detecting mutations more broadly D PCR used to amplify all exons and surrounding splice sites D Heteroduplex formation screening and/or sequencing D Analysis for large deletions and duplications D Cost ~ $2,500

22. Acute Exacerbations of CF Lung Disease v Symptoms D Increased cough with sputum production D Hemoptysis D Increased shortness of breath D Fever (not required) D Reduction in FEV1 D Worsening infiltrates on chest x-ray (not required)

23. Acute Exacerbations of CF Lung Disease v Antibiotic treatment D Oral antibiotics ; If symptoms are mild, and ; Bacteria are susceptible D Intravenous antibiotics otherwise

24. Management of Chronic Lung Disease in Cystic Fibrosis

25. Aerosolized Antibiotics v High dose tobramycin proven for chronic infection D TOBI ® 300 mg in 5 ml bid every other month Ramsey B, et al. NEJM 1999;340:23-30

26. Mucolytic Therapy for CF v DNase (Pulmozyme ® ) D Chronic use improves FEV1 and causes fewer exacerbations Fuchs HJ, et al. NEJM 1994;331:637-642

27. Bronchodilators in CF v No studies in acute exacerbations but routinely given v Chronic use -- FEV1 improves acutely in some patients   -adrenergic agonists (e.g. albuterol, salmeterol) D Anticholinergic agents (ipratroprium bromide, tiotroprium)

28. Anti-Inflammatory Treatment in CF v Glucocorticoids D Oral (prednisone) ; Preserves lung function, but too many adverse effects D Inhaled ; Used for subgroup of with bronchial hyperreactivity (asthma) symptoms v Ibuprofen D Beneficial for young patients D No evidence for improvement in adults

29. Macrolide Therapy for CF v Azithromycin in CF D Improved FEV1 D Fewer exacerbations of CF lung disease D Uncertain mechanism of action ; Anti-inflammatory? ; Bacterial toxin or biofilm production? 04122428 -4 -2 0 2 4 5 Study Week Azithromycin Placebo 1 -3 3 Change in FEV 1 (% predicted) 81620 Saiman L, et al. JAMA. 2003;290:1749-56

30. Nebulized Hypertonic Saline (7%) Elkins MR et al. N Engl J Med 2006;354:229-240 v Effect on FEV1 D Randomized, double- blind, placebo controlled trial D N = 164 D Inhalation of 4 ml of 7% vs. 0.9% saline bid for 48 weeks

31. Effect of 7% Saline on Frequency of Pulmonary Exacerbations Elkins MR et al. N Engl J Med 2006;354:229-240

32. Physiotherapy for CF v No studies in acute exacerbations D But “standard of care” treatment v Beneficial for chronic management

33. Physiotherapy Options for CF Flutter Acapella PEP Vest

34. Supplemental Oxygen v Use same guidelines as COPD

35. Home Versus Hospital Therapy for Acute Exacerbation v Home regimen must duplicate full hospital program D IV drugs D Physiotherapy D Nutrition D Et cetera v Results from small studies showed mixed results

36. Assisted Ventilation in CF v Past studies show very poor outcomes v Non-invasive ventilation being used as a bridge to lung transplantation

37. Lung Transplantation CF v Bilateral lung transplantation v Outcome similar to non-CF transplantation v Problems D Long waiting lists D Many exclusions v Living donor transplants

38. Number of CF Patients With Lung Transplants 1988 - 2005 Source Undetermined

39. Median Predicted Survival for Cystic Fibrosis 0 5 10 15 20 25 30 35 1940195019601970198019902000 Calendar Year Age, yr Source Undetermined

40. New Therapies for CF Under Development – September 2007 Source Undetermined

41. Cystic Fibrosis 1989 Clip of Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping from Science, September 1989, removed Science, September 1989

42. Cystic Fibrosis Now Image of Dan Bessette, the child from the September 1989 cover of Science, a 19 year old college sophomore in 2003

43. References v Simon RH. Treatment of CF lung disease. UpToDate, 2008. v Davis P. v Davis P. Cystic Fibrosis Since 1938. Am J Respir Crit Care Med 2006;173: 475-482.

44. Additional Source Information for more information see: http://open.umich.edu/wiki/CitationPolicy Slide 5: Science, September 1989 Slide 6: Genetic Disorder Research Project Wiki Site, http://runkle-science.wikispaces.com/Cystic+Fibrosishttp://runkle-science.wikispaces.com/Cystic+Fibrosis Slide 8: Knowles & Boucher 2002;109:571 Slide 9: Knowles & Boucher 2002;109:571 Slide 10: Source Undetermined Slide 11: Knowles & Boucher 2002;109:571 Slide 12: R. Simon Slide 13: Source Undetermined; R. Simon Slide 14: Cystic Fibrosis Foundation Patient Registry Data. 2005 Slide 18: Shwachman H, Mahmoodian A. Mod Prob Pediatr 1967;10:158 Slide 19: CF Genetic Analysis Consortium Slide 25: Ramsey B, et al. NEJM 1999;340:23-30 Slide 26: Fuchs HJ, et al. NEJM 1994;331:637-642 Slide 29: Saiman L, et al. JAMA. 2003;290:1749-56 Slide 30: Elkins MR et al. N Engl J Med 2006;354:229-240 Slide 31: Elkins MR et al. N Engl J Med 2006;354:229-240 Slide 38: Source Undetermined Slide 39: Source Undetermined Slide 40: Source Undetermined Slide 41: Science, September 1989